TY - JOUR T1 - ▼Nateglinide and ▼repaglinide for type 2 diabetes? JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 52 LP - 54 DO - 10.1136/dtb.2003.41752 VL - 41 IS - 7 A2 - , Y1 - 2003/07/01 UR - http://dtb.bmj.com/content/41/7/52.abstract N2 - Relevant BNF section: 6.1.2.3▼Nateglinide (Starlix - Novartis) and ▼repaglinide (NovoNorm - Novo Nordisk) are two of a new class of orally active antidiabetic drugs, the meglitinides. They have a rapid-onset and short-lasting stimulating effect on insulin secretion. Both are licensed for combination therapy with metformin in patients with type 2 diabetes mellitus who are inadequately controlled by maximally tolerated doses of metformin alone. In addition, repaglinide is licensed for use as monotherapy in patients with type 2 diabetes whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Here we discuss whether repaglinide and nateglinide offer worthwhile advantages in the management of patients with type 2 diabetes. ER -